Naveen Pemmaraju

List of Publications by Year
in descending order

230 papers	8,334 citations	57758 44 h-index	66911 78 g-index
233 all docs	233 docs citations	233 times ranked	7961 citing authors

#	Article	IF	Citations
1	Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplantation, 2022, 57, 51-56.	2.4	19
2	SOHO State of the Art Updates and Next Questions: Novel Therapies in Development for Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 210-223.	0.4	9
3	Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm. American Journal of Hematology, 2022, 97, E62.	4.1	17
4	Sex-BiasedZRSR2Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis. Cancer Discovery, 2022, 12, 522-541.	9.4	44
5	Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opinion on Pharmacotherapy, 2022, 23, 431-438.	1.8	3
6	Improved survival of patients with myelofibrosis in the last decade: Singleâ€center experience. Cancer, 2022, , .	4.1	16
7	Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD. Blood Advances, 2022, 6, 3027-3035.	5.2	17
8	Improved outcomes among newly diagnosed patients with <scp>FMSâ€like tyrosine kinase 3 internal tandem duplication</scp> mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification. American Journal of Hematology, 2022, 97, 329-337.	4.1	15
9	Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2022, 97, 574-582.	4.1	9
10	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. Journal of Clinical Oncology, 2022, 40, 1671-1680.	1.6	60
11	Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleosideâ€“based low-intensity therapy. Blood Advances, 2022, 6, 5546-5549.	5.2	1
12	Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. Leukemia, 2022, 36, 1343-1350.	7.2	23
13	<scp>Treatmentâ€free</scp> remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors. American Journal of Hematology, 2022, 97, 856-864.	4.1	33
14	Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia. Leukemia Research, 2022, 115, 106809.	0.8	15
15	Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. American Journal of Hematology, 2022, 97, 885-894.	4.1	4
16	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. Leukemia and Lymphoma, 2022, 63, 2161-2170.	1.3	12
17	Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells. Nature Communications, 2022, 13, 2228.	12.8	14
18	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study. Lancet Haematology,the, 2022, 9, e350-e360.	4.6	26

#	Article	IF	Citations
19	Hypomethylating agent and venetoclax with FLT3 inhibitor â€œtripletâ€•therapy in older/unfit patients with FLT3 mutated AML. Blood Cancer Journal, 2022, 12, 77.	6.2	33
20	CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2022, 14, 2287.	3.7	6
21	Defining disease modification in myelofibrosis in the era of targeted therapy. Cancer, 2022, 128, 2420-2432.	4.1	24
22	Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematology,the, 2022, 9, e434-e444.	4.6	18
23	Venetoclax combined with <scp>FLAGâ€IDA</scp> induction and consolidation in newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2022, 97, 1035-1043.	4.1	31
24	Major Clinical Response in a Patient with Leukemia Cutis Treated with the Bromodomain Inhibitor PLX51107 and Azacitidine. Leukemia Research, 2022, 119, 106884.	0.8	1
25	Blastic plasmacytoid dendritic cell neoplasm (<scp>BPDCN</scp>): A promising future in the era of targeted therapeutics. Cancer, 2022, 128, 3019-3026.	4.1	9
26	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology, 2022, 40, 3848-3857.	1.6	41
27	Immunophenotypic and Molecular Features of Acute Myeloid Leukemia with Plasmacytoid Dendritic Cell Differentiation Are Distinct from Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2022, 14, 3375.	3.7	8
28	Blastic plasmacytoid dendritic cell neoplasm (BPDCN) arising in the setting of polycythemia vera (PV): An illustration of the emerging role of flow cytometry analysis in monitoring progression of myeloproliferative neoplasms. EJHaem, 2022, 3, 954-957.	1.0	5
29	Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. Journal of Clinical Oncology, 2022, 40, 3032-3036.	1.6	19
30	Immunophenotypic characterization of reactive and neoplastic plasmacytoid dendritic cells permits establishment of a 10-color flow cytometric panel for initial workup and residual disease evaluation of blastic plasmacytoid dendritic cell neoplasm. Haematologica, 2021, 106, 1047-1055.	3.5	40
31	Treating Leukemia in the Time of COVID-19. Acta Haematologica, 2021, 144, 132-145.	1.4	57
32	Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E50-E53.	4.1	8
33	Treating Rosaiâ€“Dorfman disease and RASâ€associated autoimmune leucoproliferative disorder with malignant transformation. British Journal of Haematology, 2021, 192, 667-671.	2.5	2
34	Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatmentâ€related mortality. American Journal of Hematology, 2021, 96, 282-291.	4.1	59
35	Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 Inhibitors. Blood Cancer Discovery, 2021, 2, 125-134.	5.0	50
36	Bromodomain and extra-terminal (BET) inhibitors in treating myeloid neoplasms. Leukemia and Lymphoma, 2021, 62, 528-537.	1.3	15

#	Article	IF	Citations
37	Myeloproliferative neoplasm questionnaire: assessing patient disease knowledge in the modern digital information era. Leukemia and Lymphoma, 2021, 62, 2253-2260.	1.3	5
38	Targeting the p-D-C: easy as C-D-1-2-3?. Blood, 2021, 137, 1277-1278.	1.4	9
39	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nature Reviews Clinical Oncology, 2021, 18, 313-319.	27.6	103
40	The Democratization of Scientific Conferences: Twitter in the Era of COVID-19 and Beyond. Current Hematologic Malignancy Reports, 2021, 16, 132-139.	2.3	8
41	Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (<scp>MDS/MPNâ€RSâ€T</scp>) and myelodysplastic syndrome with ring sideroblasts (<scp>MDSâ€RS</scp>). American Journal of Hematology, 2021, 96, E246-E249.	4.1	9
42	Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs. Blood Advances, 2021, 5, 2156-2164.	5.2	33
43	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica, 2021, 106, 2121-2130.	3.5	34
44	Immunotherapy and Immunomodulation in Myeloproliferative Neoplasms. Hematology/Oncology Clinics of North America, 2021, 35, 409-429.	2.2	3
45	A call to action for the treatment of acute promyelocytic leukemia in the modern era: It is no longer just about the ATRA and arsenic. Cancer, 2021, 127, 2867-2869.	4.1	0
46	Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer, 2021, 127, 3113-3124.	4.1	5
47	Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin. Leukemia, 2021, 35, 3299-3303.	7.2	18
48	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Advances, 2021, 5, 1876-1883.	5.2	56
49	Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia, 2021, 35, 1494-1499.	7.2	16
50	Clinical Significance of Bone Marrow Blast Percentage in Patients With Myelofibrosis and the Effect of Ruxolitinib Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 318-327.e6.	0.4	11
51	Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer Journal, 2021, 11, 98.	6.2	24
52	Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. American Journal of Hematology, 2021, 96, 1000-1007.	4.1	23
53	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia, 2021, 35, 3421-3429.	7.2	22
54	Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy. Leukemia and Lymphoma, 2021, 62, 2568-2586.	1.3	10

#	Article	IF	Citations
55	Longâ€term results of lowâ€intensity chemotherapy with clofarabine or cladribine combined with lowâ€dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2021, 96, 914-924.	4.1	13
56	Chronic Myelomonocytic Leukemia: Hematopathology Perspective. Journal of Immunotherapy and Precision Oncology, 2021, 4, 142-149.	1.4	1
57	Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm. Blood, 2021, 138, 1373-1377.	1.4	31
58	A phase 1b/2 study of azacitidine with PDâ€L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. Cancer, 2021, 127, 3761-3771.	4.1	34
59	Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia. Blood, 2021, 138, 1733-1739.	1.4	19
60	Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 734-740.	0.4	23
61	Outcomes in patients with newly diagnosed TP53â€mutated acute myeloid leukemia with or without venetoclaxâ€based therapy. Cancer, 2021, 127, 3541-3551.	4.1	40
62	Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Advances, 2021, 5, 3163-3173.	5.2	17
63	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematology,the, 2021, 8, e552-e561.	4.6	81
64	Tenâ€day decitabine with venetoclax versus intensive chemotherapy in relapsed or refractory acute myeloid leukemia: A propensity scoreâ€matched analysis. Cancer, 2021, 127, 4213-4220.	4.1	24
65	CD303 (BDCA-2) â€“ a potential novel target for therapy in hematologic malignancies. Leukemia and Lymphoma, 2021, , 1-12.	1.3	6
66	#JACCCardioOnc. JACC: CardioOncology, 2021, 3, 461-464.	4.0	2
67	Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia. Journal of Clinical Oncology, 2021, 39, 2768-2778.	1.6	173
68	Targeting CD123 in BPDCN: an emerging field. Expert Review of Hematology, 2021, 14, 993-1004.	2.2	8
69	Integrated Clinical Genotype-Phenotype Characteristics of Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2021, 13, 5888.	3.7	15
70	Safety and Efficacy of Combining Tagraxofusp (SL-401) with Azacitidine or Azacitidine and Venetoclax in a Phase 1b Study for CD123 Positive AML, MDS, or BPDCN. Blood, 2021, 138, 2346-2346.	1.4	21
71	How to Treat Adult Acute MyeloidÂLeukemia. JACC: CardioOncology, 2021, 3, 747-751.	4.0	2
72	Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN). Expert Opinion on Biological Therapy, 2020, 20, 115-123.	3.1	10

#	Article	IF	Citations
73	Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. Leukemia Research, 2020, 98, 106445.	0.8	1
74	Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. Journal of Hematology and Oncology, 2020, 13, 132.	17.0	18
75	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology,the, 2020, 7, e724-e736.	4.6	201
76	Atypical cases of necrotizing sweet syndrome in patients with myelodysplastic syndrome and acute myeloid leukaemia. British Journal of Haematology, 2020, 191, e10-e13.	2.5	2
77	Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era. Cancer, 2020, 126, 4322-4331.	4.1	19
78	Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2775-2777.	1.3	4
79	Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leukemia and Lymphoma, 2020, 61, 3018-3020.	1.3	6
80	Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia. American Journal of Hematology, 2020, 95, 1288-1295.	4.1	28
81	Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials. Expert Opinion on Emerging Drugs, 2020, 25, 491-499.	2.4	6
82	Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. Lancet Haematology,the, 2020, 7, e523-e533.	4.6	43
83	Leveraging Social Media for Cardio-Oncology. Current Treatment Options in Oncology, 2020, 21, 83.	3.0	14
84	Social Media for Hematopathologists: Medical Practice Reinventedâ€"#Hemepath. Current Hematologic Malignancy Reports, 2020, 15, 383-390.	2.3	9
85	Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3). American Journal of Hematology, 2020, 95, E326-E329.	4.1	2
86	Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Advances, 2020, 4, 4020-4027.	5.2	48
87	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. American Journal of Hematology, 2020, 95, E313-E315.	4.1	4
88	AML-373: Tagraxofusp, a CD123-Targeted Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Results of a Landmark Clinical Trial. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S209-S210.	0.4	1
89	MPN-379: Interim Results from an Ongoing Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Chronic Myelomonocytic Leukemia (CMML). Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S339.	0.4	1
90	Impact of <scp>CD33</scp> and <scp>ABCB1</scp> single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. American Journal of Hematology, 2020, 95, E225-E228.	4.1	9

#	Article	IF	Citations
91	Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm. Hematology/Oncology Clinics of North America, 2020, 34, 565-574.	2.2	12
92	Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies. Hematological Oncology, 2020, 38, 654-664.	1.7	3
93	Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm. Expert Review of Anticancer Therapy, 2020, 20, 543-550.	2.4	10
94	A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia. Leukemia, 2020, 34, 2489-2492.	7.2	37
95	Clinical value of event-free survival in acute myeloid leukemia. Blood Advances, 2020, 4, 1690-1699.	5.2	4
96	Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Advances, 2020, 4, 482-495.	5.2	86
97	Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Advances, 2020, 4, 1311-1320.	5.2	106
98	The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. Blood, 2020, 136, 49-50.	1.4	21
99	Phase 2 Study of Tagraxofusp Therapy for BPDCN Patients Post-Autologous or Post-Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 5-5.	1.4	2
100	A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis. Blood, 2020, 136, 39-40.	1.4	10
101	Male-Biased Spliceosome Mutations in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Impair pDC Activation and Apoptosis. Blood, 2020, 136, 13-14.	1.4	1
102	Impact of COVID19 Pandemic on an International MPN Patient Population: Survey Results from 1560 MPN Patients. Blood, 2020, 136, 1-3.	1.4	1
103	Ameli-01: Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (allogeneic engineered T-cells expressing) Tj ETQq1 1 0.784314 rgBT /Overlock Myeloid Leukemia. Blood, 2020, 136, 41-42.	1.4	7
104	Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2020, 136, 11-13.	1.4	16
105	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood, 2020, 136, 42-43.	1.4	11
106	Trial in Progress: Phase Ib/II Study of Bcl-2/Bcl-Xl Inhibitor Pelcitoclax (APG-1252) in Patients with Myelofibrosis (MF) That Progressed after Initial Therapy. Blood, 2020, 136, 15-16.	1.4	3
107	Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors. Current Hematologic Malignancy Reports, 2019, 14, 460-468.	2.3	14
108	Sudden blastic transformation in treatmentâ€free remission chronic myeloid leukaemia. British Journal of Haematology, 2019, 187, 543-545.	2.5	24

#	Article	IF	Citations
109	Plesiomonas shigelloidesgastroenteritis in a patient with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 3341-3342.	1.3	3
110	Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm. Expert Review of Clinical Pharmacology, 2019, 12, 941-946.	3.1	19
111	Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm. Therapeutic Advances in Hematology, 2019, 10, 204062071987473.	2.5	14
112	Ibrutinib and Venetoclax for First-Line Treatment of CLL. New England Journal of Medicine, 2019, 380, 2095-2103.	27.0	388
113	Topoisomerase II inhibitors in AML: past, present, and future. Expert Opinion on Pharmacotherapy, 2019, 20, 1637-1644.	1.8	25
114	Prognostic significance of baseline FLT3â€ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib. American Journal of Hematology, 2019, 94, 984-991.	4.1	32
115	PD1/PD-L1 Expression in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancers, 2019, 11, 695.	3.7	12
116	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. New England Journal of Medicine, 2019, 380, 1628-1637.	27.0	274
117	Patient with mixed-phenotype acute leukemia with CBFB rearrangement. Leukemia and Lymphoma, 2019, 60, 2829-2831.	1.3	0
118	<scp>SMAC</scp> mimetics as potential cancer therapeutics in myeloid malignancies. British Journal of Haematology, 2019, 185, 219-231.	2.5	29
119	Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood, 2019, 133, 2348-2351.	1.4	43
120	Features of non-activation dendritic state and immune deficiency in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood Cancer Journal, 2019, 9, 99.	6.2	26
121	Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Current Hematologic Malignancy Reports, 2019, 14, 515-522.	2.3	10
122	Dual Expression of TCF4 and CD123 Is Highly Sensitive and Specific For Blastic Plasmacytoid Dendritic Cell Neoplasm. American Journal of Surgical Pathology, 2019, 43, 1429-1437.	3.7	59
123	Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discovery, 2019, 9, 370-383.	9.4	380
124	Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood Cancer Journal, 2019, 9, 4.	6.2	57
125	Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience. Journal of Hematology and Oncology, 2019, 12, 1.	17.0	257
126	Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome. Blood, 2019, 134, 1391-1391.	1.4	3

#	Article	IF	Citations
127	Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study. Blood, 2019, 134, 4163-4163.	1.4	25
128	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood, 2019, 134, 2637-2637.	1.4	15
129	Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2019, 134, 734-734.	1.4	40
130	Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis. Blood, 2019, 134, 4178-4178.	1.4	4
131	Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with Myelofibrosis. Blood, 2019, 134, 1656-1656.	1.4	5
132	Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis. Blood, 2019, 134, 558-558.	1.4	19
133	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era. Blood, 2019, 134, 2723-2723.	1.4	14
134	Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.. Journal of Clinical Oncology, 2019, 37, 7058-7058.	1.6	6
135	Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies. Clinical Hematology International, 2019, 1, 2.	1.7	8
136	Final results of a phase 2, openâ€label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and highâ€risk myelodysplastic syndrome. Cancer, 2018, 124, 2758-2765.	4.1	78
137	8q24/MYC rearrangement is a recurrent cytogenetic abnormality in blastic plasmacytoid dendritic cell neoplasms. Leukemia Research, 2018, 66, 73-78.	0.8	29
138	A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 813-820.	1.3	16
139	Hyperâ€CVAD plus nelarabine in newly diagnosed adult Tâ€cell acute lymphoblastic leukemia and Tâ€lymphoblastic lymphoma. American Journal of Hematology, 2018, 93, 91-99.	4.1	74
140	Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Reviews, 2018, 32, 96-105.	5.7	35
141	Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. American Journal of Hematology, 2018, 93, 84-90.	4.1	40
142	Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. European Journal of Haematology, 2018, 100, 257-263.	2.2	40
143	Glioblastoma and acute myeloid leukemia: malignancies with striking similarities. Journal of Neuro-Oncology, 2018, 136, 223-231.	2.9	18
144	Clinical experience with the <scp>BCL</scp>2â€inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. American Journal of Hematology, 2018, 93, 401-407.	4.1	336

#	Article	IF	Citations
145	A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms. American Journal of Hematology, 2018, 93, 277-285.	4.1	54
146	Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Annals of Hematology, 2018, 97, 109-121.	1.8	27
147	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1788-1797.	1.6	156
148	Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. Lancet Haematology,the, 2018, 5, e618-e627.	4.6	190
149	Early detection of transformation to BPDCN in a patient with MDS. Experimental Hematology and Oncology, 2018, 7, 26.	5.0	13
150	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCNâ€"Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community. Current Hematologic Malignancy Reports, 2018, 13, 581-587.	2.3	10
151	International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood, 2018, 132, 2115-2124.	1.4	232
152	Epidemiology and survival of blastic plasmacytoid dendritic cell neoplasm. Leukemia Research, 2018, 73, 21-23.	0.8	62
153	A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood, 2018, 132, 1664-1674.	1.4	62
154	Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Advances, 2018, 2, 1807-1816.	5.2	34
155	The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Annals of Hematology, 2018, 97, 2071-2080.	1.8	32
156	Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. American Journal of Hematology, 2018, 93, E357-E360.	4.1	2
157	Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial. Lancet Haematology,the, 2018, 5, e411-e421.	4.6	66
158	Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models. Blood, 2018, 132, 3956-3956.	1.4	4
159	Phase I Study of Palbociclib Alone and in Combination in Patients with Relapsed and Refractory (R/R) Leukemias. Blood, 2018, 132, 4057-4057.	1.4	10
160	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. Blood, 2018, 132, 1773-1773.	1.4	3
161	Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). Blood, 2018, 132, 1821-1821.	1.4	12
162	LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial. Blood, 2018, 132, 687-687.	1.4	14

#	Article	IF	Citations
163	Mixed angioinvasive exserohilum and scedosporium infection in a patient with AML. American Journal of Hematology, 2017, 92, 119-120.	4.1	2
164	An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes. American Journal of Hematology, 2017, 92, 674-682.	4.1	24
165	Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. American Journal of Hematology, 2017, 92, 845-850.	4.1	36
166	Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents. American Journal of Hematology, 2017, 92, 599-606.	4.1	38
167	<scp>S</scp>ignificance of recurrence of minimal residual disease detected by multiâ€parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission. American Journal of Hematology, 2017, 92, 279-285.	4.1	32
168	Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax. Cancer Discovery, 2017, 7, 156-164.	9.4	164
169	Editorial overview: Emerging importance of social media for real-time communication in the modern medical era. Seminars in Hematology, 2017, 54, 175-176.	3.4	7
170	Clinical outcomes in adult patients with aplastic anemia: A single institution experience. American Journal of Hematology, 2017, 92, 1295-1302.	4.1	13
171	The use and impact of Twitter at medical conferences: Best practices and Twitter etiquette. Seminars in Hematology, 2017, 54, 184-188.	3.4	39
172	A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients. Scientific Reports, 2017, 7, 11253.	3.3	52
173	Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Haematologica, 2017, 102, 1709-1717.	3.5	13
174	A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer, 2017, 123, 4430-4439.	4.1	37
175	Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN. Current Hematologic Malignancy Reports, 2017, 12, 592-597.	2.3	13
176	Novel Pathways and Potential Therapeutic Strategies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): CD123 and Beyond. Current Hematologic Malignancy Reports, 2017, 12, 510-512.	2.3	29
177	Rare Cancers and Social Media: Analysis of Twitter Metrics in the First 2ÂYears of a Rare-Disease Community for Myeloproliferative Neoplasms on Social Mediaâ€"#MPNSM. Current Hematologic Malignancy Reports, 2017, 12, 598-604.	2.3	22
178	Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study. Leukemia and Lymphoma, 2017, 58, 866-871.	1.3	4
179	<scp>PET</scp>â€positive lymphadenopathy in <scp>CLL</scp>â€"Not always <scp>R</scp>ichter transformation. American Journal of Hematology, 2017, 92, 405-406.	4.1	8
180	BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia, 2017, 31, 678-687.	7.2	77

#	Article	IF	Citations
181	Analysis of the Use and Impact of Twitter During American Society of Clinical Oncology Annual Meetings From 2011 to 2016: Focus on Advanced Metrics and User Trends. Journal of Oncology Practice, 2017, 13, e623-e631.	2.5	58
182	Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. Leukemia Research, 2017, 59, 110-116.	0.8	53
183	Questions on asparaginase-associated pancreatitis. Lancet Oncology, The, 2017, 18, 1148-1149.	10.7	2
184	Disease-specific hashtags and the creation of Twitter medical communities in hematology and oncology. Seminars in Hematology, 2017, 54, 189-192.	3.4	24
185	Social Media and Myeloproliferative Neoplasms (MPN): Analysis of Advanced Metrics From the First Year of a New Twitter Community: #MPNSM. Current Hematologic Malignancy Reports, 2016, 11, 456-461.	2.3	19
186	Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Current Hematologic Malignancy Reports, 2016, 11, 462-467.	2.3	14
187	Successful treatment of aplastic anemiaâ€“paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clinical Case Reports (discontinued), 2016, 4, 765-767.	0.5	3
188	Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 213-222.e2.	0.4	26
189	Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer. Current Hematologic Malignancy Reports, 2016, 11, 449-455.	2.3	91
190	DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma, 2016, 57, 1969-1973.	1.3	3
191	Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival forÂPatients with Chronic Myelomonocytic Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 47-53.	2.0	58
192	Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF). Blood, 2016, 128, 3105-3105.	1.4	15
193	Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2016, 128, 4039-4039.	1.4	18
194	Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.. Journal of Clinical Oncology, 2016, 34, 7006-7006.	1.6	11
195	The Sacred Trust. American Journal of Kidney Diseases, 2015, 66, A17-A19.	1.9	0
196	Identification of a Novel Fusion Gene,IRF2BP2-RARA, in Acute Promyelocytic Leukemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 19-22.	4.9	46
197	Durable remission with rituximab in a patient with an unusual variant of <scp>C</scp>astleman's disease with myelofibrosisâ€"<scp>TAFRO</scp> syndrome. American Journal of Hematology, 2015, 90, 1091-1092.	4.1	26
198	Disseminated histoplasmosis as pseudo <scp>R</scp>ichter's transformation in a patient with chronic lymphocytic leukemia. American Journal of Hematology, 2015, 90, 752-753.	4.1	8

#	Article	IF	Citations
199	From Philadelphia-Negative to JAK2-Positive: Effect of Genetic Discovery on Risk Stratification and Management. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 139-145.	3.8	6
200	Social Media and Myeloproliferative Neoplasms (MPN)â€"Focus on Twitter and the Development of a Disease-specific Community: #MPNSM. Current Hematologic Malignancy Reports, 2015, 10, 413-420.	2.3	22
201	Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 110-114.	0.4	35
202	Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience. American Journal of Hematology, 2015, 90, 27-30.	4.1	38
203	Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 358-363.	0.4	50
204	Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematology,the, 2015, 2, e186-e193.	4.6	227
205	Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase. Leukemia Research, 2015, 39, 950-956.	0.8	69
206	Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. British Journal of Haematology, 2015, 168, 646-653.	2.5	64
207	Healing words. Cmaj, 2015, 187, 360-361.	2.0	0
208	Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes. Blood, 2015, 126, 3746-3746.	1.4	11
209	Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid Leukemia (AML). Blood, 2015, 126, 3795-3795.	1.4	15
210	MutatedNPM1in patients with acute myeloid leukemia in remission and relapse. Leukemia and Lymphoma, 2014, 55, 1337-1344.	1.3	28
211	Chronic Myeloid Leukemia in Adolescents and Young Adults: Patient Characteristics, Outcomes and Review of the Literature. Acta Haematologica, 2014, 132, 298-306.	1.4	19
212	A Single Case of RosaiÃ¢â‚¬â€œDorfman Disease Marked by Pathologic Fractures, Kidney Failure, and Liver Cirrhosis Treated with Single-Agent Cladribine. Frontiers in Oncology, 2014, 4, 297.	2.8	10
213	Disseminated <scp>S</scp>aprochaete capitata (formerly known as <scp>G</scp>eotrichum) Tj ETQq1 1 0.784314 rgBT /O leukemia. European Journal of Haematology, 2014, 93, 543-544.	2.2	12
214	Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia. Leukemia Research, 2014, 38, 1126-1129.	0.8	29
215	Augmented Berlinâ€Frankfurtâ€MÃ¼nster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL). Cancer, 2014, 120, 3660-3668.	4.1	91
216	Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood, 2014, 124, 385-392.	1.4	195

#	Article	IF	Citations
217	Characteristics of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Male predominance, propensity for extramedullary involvement, and poor outcomes.. Journal of Clinical Oncology, 2014, 32, 7118-7118.	1.6	3
218	Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients â‰¥60 years with newly diagnosed acute myeloid leukemia. American Journal of Hematology, 2013, 88, 961-966.	4.1	46
219	Outcomes in Patients With Relapsed or Refractory Acute Promyelocytic Leukemia Treated With or Without Autologous or Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 485-492.	0.4	25
220	Primary autoimmune myelofibrosis (MF) with high-grade peripheral T-cell lymphoma (PTCL) NOS. European Journal of Haematology, 2013, 91, n/a-n/a.	2.2	4
221	TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. American Journal of Hematology, 2013, 88, 1055-1061.	4.1	120
222	Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia. Blood, 2013, 122, 2807-2811.	1.4	50
223	An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2013, 122, 2682-2682.	1.4	7
224	Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica, 2012, 97, 1029-1035.	3.5	74
225	Abdominal venous thrombosis presenting in myeloproliferative neoplasm with JAK2 V617F mutation: a case report. Journal of Medical Case Reports, 2012, 6, 102.	0.8	4
226	Analysis of outcomes of patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN).. Journal of Clinical Oncology, 2012, 30, 6578-6578.	1.6	10
227	Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders. Haematologica, 2010, 95, 1090-1097.	3.5	79
228	Solifenacin-induced small bowel pseudo-obstruction. Journal of Hospital Medicine, 2008, 3, 176-178.	1.4	3
229	Acute Myeloid Leukemia in Adolescents and Young Adults (AYA): The MD Anderson Cancer Center (MDACC) Experience. Blood, 2008, 112, 3982-3982.	1.4	8
230	Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Modern Pathology, 0, , .	5.5	0